<!DOCTYPE html><html lang="en" class="__variable_6d343d __variable_49a339"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1"/><link rel="preload" href="/_next/static/media/26d4368bf94c0ec4-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" href="/_next/static/media/36966cca54120369-s.p.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="preload" as="image" href="/logo.svg" fetchPriority="high"/><link rel="stylesheet" href="/_next/static/css/505959d5a855b2ce.css" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" href="/_next/static/chunks/webpack-04cc3a393714a88b.js"/><script src="/_next/static/chunks/fd9d1056-4b87d5bb1aa946b3.js" async=""></script><script src="/_next/static/chunks/23-7a13f39f0e990758.js" async=""></script><script src="/_next/static/chunks/main-app-9c6ab80fd9a4d8e3.js" async=""></script><script src="/_next/static/chunks/231-9e11bdfe3b664aec.js" async=""></script><script src="/_next/static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js" async=""></script><script src="/_next/static/chunks/896-78f6f35c40d7ae60.js" async=""></script><script src="/_next/static/chunks/app/layout-24f8abeacb8025a3.js" async=""></script><link rel="icon" href="/logo.svg" type="image/svg+xml"/><title>AVH share price, analysis &amp; company profile - Avita Medical Inc. | ASX Desk</title><meta name="description" content="Latest AVH share price overview, what Avita Medical Inc. does, bull and bear cases, and AI-powered analysis for ASX investors."/><link rel="canonical" href="https://asxdesk.com/asx/AVH/"/><meta property="og:title" content="AVH share price, analysis &amp; company profile - Avita Medical Inc."/><meta property="og:description" content="Latest AVH share price overview, what Avita Medical Inc. does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta property="og:url" content="https://asxdesk.com/asx/AVH/"/><meta property="og:type" content="article"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="AVH share price, analysis &amp; company profile - Avita Medical Inc."/><meta name="twitter:description" content="Latest AVH share price overview, what Avita Medical Inc. does, bull and bear cases, and AI-powered analysis for ASX investors."/><meta name="next-size-adjust"/><script src="/_next/static/chunks/polyfills-78c92fac7aa8fdd8.js" noModule=""></script></head><body class="min-h-screen bg-ink-900 text-slate-100"><div class="min-h-screen"><header class="sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur"><div class="mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8"><a class="flex items-center gap-3" href="/"><img alt="ASX Desk" fetchPriority="high" width="140" height="40" decoding="async" data-nimg="1" class="h-10 w-auto" style="color:transparent" src="/logo.svg"/><span class="hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline">Research Terminal</span></a><nav class="hidden items-center gap-6 text-sm text-slate-300 md:flex"><a class="transition hover:text-white" href="/">Home</a><a class="transition hover:text-white" href="/screener/">Screener</a><a class="transition hover:text-white" href="/sectors/">Sectors</a><a class="transition hover:text-white" href="/news/">News</a><a class="transition hover:text-white" href="/compare/BHP-vs-RIO/">Compare</a><a class="transition hover:text-white" href="/about/">About</a></nav><div class="hidden items-center gap-3 md:flex"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search ticker…" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div><button class="rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20">Premium Research</button><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400">Open Account</button></div></div><div class="flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden"><div class="flex-1"><div class="relative"><div class="flex items-center rounded-full border border-white/10 bg-ink-900/70 px-3 py-1.5 focus-within:border-blue-500/60 transition"><svg class="h-4 w-4 shrink-0 text-slate-500" fill="none" stroke="currentColor" viewBox="0 0 24 24" stroke-width="2"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35" stroke-linecap="round"></path></svg><input type="text" placeholder="Search ticker…" class="ml-2 w-36 bg-transparent text-xs text-white placeholder:text-slate-500 focus:outline-none lg:w-44" value=""/></div></div></div><a class="shrink-0 text-xs text-blue-300" href="/screener/">Screener</a></div></header><main class="mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8"><div class="space-y-12"><script type="application/ld+json">{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does AVH do?","acceptedAnswer":{"@type":"Answer","text":"Avita Medical develops and commercialises the RECELL System, an innovative regenerative medicine technology. This system uses a small sample of a patient's own skin to create a 'spray-on skin' solution, primarily for treating severe burns, and increasingly for vitiligo and other reconstructive skin procedures."}},{"@type":"Question","name":"Is AVH a good investment?","acceptedAnswer":{"@type":"Answer","text":"AVH represents a speculative investment opportunity within the ASX biotech sector. It offers significant potential upside through the expanded adoption of its RECELL System and successful development of new indications. However, like many small-cap biotechs, it carries inherent risks, including dependence on clinical trial success, regulatory hurdles, market acceptance, and the ongoing need for capital raises to fund its growth ambitions."}},{"@type":"Question","name":"What drives AVH's share price?","acceptedAnswer":{"@type":"Answer","text":"AVH's share price is primarily driven by several factors specific to the biotech sector: growth in RECELL System sales, positive outcomes and progress from clinical trials for new indications, regulatory approvals (particularly from the FDA), news regarding reimbursement pathways, and the company's ability to effectively manage its cash burn and secure funding for ongoing research and commercial expansion."}}]}</script><section class="grid gap-8 lg:grid-cols-[1.6fr_0.8fr]"><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><p class="text-xs uppercase tracking-[0.3em] text-blue-300">Health Care</p><h1 class="mt-3 font-display text-3xl font-semibold">Avita Medical Inc.<!-- --> (<!-- -->AVH<!-- -->)</h1><p class="mt-4 text-sm text-slate-300">Avita Medical Inc. is a regenerative medicine company developing and commercialising the RECELL System, a medical device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of a patient’s own skin. This innovative technology is primarily used for the treatment of acute thermal burns, with expanding applications in vitiligo and reconstructive procedures, and its commercial operations are predominantly focused in the United States.</p><div class="mt-6 grid gap-4 sm:grid-cols-2"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Market Cap</p><p class="mt-2 text-lg font-semibold">A$186M</p></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><p class="text-xs text-slate-500">Shares on Issue</p><p class="mt-2 text-lg font-semibold">N/A</p></div></div><div class="mt-6 flex flex-wrap gap-3 text-xs text-slate-400"><a href="" class="rounded-full border border-white/10 px-3 py-1">Company Website</a><span class="rounded-full border border-white/10 px-3 py-1">AI coverage updated hourly</span><span class="rounded-full border border-white/10 px-3 py-1">Data from ASX filings</span></div></div><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold mb-4">Price Chart</h2><div id="tradingview-widget-AVH" style="height:700px;width:100%"><div class="flex h-full items-center justify-center"><div class="flex items-center gap-3 text-sm text-slate-400"><svg class="h-5 w-5 animate-spin text-blue-400" viewBox="0 0 24 24" fill="none"><circle cx="12" cy="12" r="10" stroke="currentColor" stroke-width="3" class="opacity-25"></circle><path d="M4 12a8 8 0 018-8" stroke="currentColor" stroke-width="3" stroke-linecap="round" class="opacity-75"></path></svg>Loading chart…</div></div></div></div><section class="space-y-6"><div class="glass-card rounded-2xl p-6"><h2 class="font-display text-xl font-semibold">AI Analysis</h2><div class="mt-4 space-y-4 text-sm text-slate-300"><p>Avita Medical is a revenue-generating small-cap biotech firm focused on expanding the adoption and indications for its proprietary RECELL System. Recent performance indicates growing revenue driven by increased product sales and market penetration, particularly within the burns treatment market in the US. The company is actively pursuing new regulatory approvals and indications, reflecting its transition from a pure R&amp;D play to a commercial-stage entity, though profitability may still be nascent as it reinvests heavily in growth and R&amp;D and requires ongoing capital management.</p><p>The growth outlook for Avita Medical is tied to broader adoption of the RECELL System across its approved indications (burns, vitiligo) and the successful expansion into new areas like soft tissue reconstruction. Upcoming catalysts include potential FDA approvals for new indications, publication of positive clinical trial data, and increased reimbursement coverage, which could significantly broaden market access. Strategically, the company is focused on scaling its commercial operations, deepening market penetration, and advancing its pipeline to leverage the RECELL technology platform for a wider range of dermatological and wound healing applications.</p></div></div><div class="grid gap-6 lg:grid-cols-2"><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-emerald-300">Bull Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>• <!-- -->Successful FDA approvals for new indications (e.g., soft tissue reconstruction, chronic wounds) and improved reimbursement pathways could significantly broaden market access and revenue potential for the RECELL System.</li><li>• <!-- -->Continued education and strong clinical data driving higher utilization rates of the RECELL System by plastic surgeons and burn specialists, leading to accelerated sales growth and deeper penetration in existing markets.</li><li>• <!-- -->Positive outcomes from ongoing or future clinical trials could de-risk the pipeline, attract further investment, and support broader commercialization efforts, potentially making AVH an acquisition target.</li></ul></div><div class="glass-card rounded-2xl p-6"><h3 class="flex items-center gap-2 text-sm font-semibold text-red-300">Bear Case</h3><ul class="mt-4 space-y-2 text-sm text-slate-300"><li>• <!-- -->Unfavourable clinical trial results or significant delays in regulatory approval processes for new indications could hinder growth, increase cash burn, and impact investor confidence.</li><li>• <!-- -->Slower-than-anticipated physician adoption due to factors like training requirements, cost-effectiveness concerns, or intense competition from alternative treatments could limit revenue growth and profitability.</li><li>• <!-- -->As a growth-stage biotech, Avita Medical may require further capital raises to fund ongoing R&amp;D and commercial expansion, potentially leading to significant shareholder dilution.</li></ul></div></div></section><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Recent Announcements</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Statement of CDIs on issue - AVH</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>4 Feb 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Capital Structure</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Notification of cessation of securities - AVH</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>2 Feb 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Capital Structure</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Change of Director&#x27;s Interest Notice</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>29 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Director Dealing</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Change of Director&#x27;s Interest Notice</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>29 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Director Dealing</span></div></div><div class="rounded-xl border border-white/10 bg-ink-900/40 p-4"><div class="flex flex-wrap items-center gap-2"><p class="font-semibold text-white">Change of Director&#x27;s Interest Notice</p></div><div class="mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500"><span>29 Jan 2026</span><span class="rounded-full border border-white/10 bg-ink-800 px-2 py-0.5">Director Dealing</span></div></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">FAQs</h3><div class="mt-4 space-y-3 text-sm text-slate-300"><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What does AVH do?</p><p class="text-slate-400">Avita Medical develops and commercialises the RECELL System, an innovative regenerative medicine technology. This system uses a small sample of a patient&#x27;s own skin to create a &#x27;spray-on skin&#x27; solution, primarily for treating severe burns, and increasingly for vitiligo and other reconstructive skin procedures.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">Is AVH a good investment?</p><p class="text-slate-400">AVH represents a speculative investment opportunity within the ASX biotech sector. It offers significant potential upside through the expanded adoption of its RECELL System and successful development of new indications. However, like many small-cap biotechs, it carries inherent risks, including dependence on clinical trial success, regulatory hurdles, market acceptance, and the ongoing need for capital raises to fund its growth ambitions.</p></div><div class="border-b border-white/5 pb-3"><p class="font-semibold text-white">What drives AVH&#x27;s share price?</p><p class="text-slate-400">AVH&#x27;s share price is primarily driven by several factors specific to the biotech sector: growth in RECELL System sales, positive outcomes and progress from clinical trials for new indications, regulatory approvals (particularly from the FDA), news regarding reimbursement pathways, and the company&#x27;s ability to effectively manage its cash burn and secure funding for ongoing research and commercial expansion.</p></div></div></div></div><div class="space-y-6"><div class="glass-card rounded-2xl p-6"><h3 class="font-semibold">Key Metrics</h3><div class="mt-4 space-y-4 text-sm"><div class="flex items-center justify-between"><span class="text-slate-400">Share Price</span><span class="font-semibold">A$<!-- -->1.14</span></div><div class="flex items-center justify-between"><span class="text-slate-400">1Y Performance</span><span class="font-semibold text-red-400">-58.3<!-- -->%</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Market Cap</span><span class="font-semibold">A$186M</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Shares on Issue</span><span class="font-semibold">N/A</span></div><div class="flex items-center justify-between"><span class="text-slate-400">Sector</span><span class="font-semibold">Health Care</span></div><div class="flex items-center justify-between"><span class="text-slate-400">IPO Date</span><span class="font-semibold">24/06/2020</span></div></div></div><div class="glass-card rounded-2xl p-6"><h3 class="font-display text-lg font-semibold">Related Stocks</h3><div class="mt-4 space-y-4"><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/CSL/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">CSL<span class="ml-2 text-sm text-slate-400">CSL Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->181.24</p><p class="text-xs font-semibold text-red-400">-27.3<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$88.2B</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/PNV/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">PNV<span class="ml-2 text-sm text-slate-400">Polynovo Ltd</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.99</p><p class="text-xs font-semibold text-red-400">-13.1<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$670M</span><span class="text-blue-300">View analysis</span></div></a><a class="group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40" href="/asx/1AD/"><div class="flex items-center justify-between"><div><p class="text-xs uppercase tracking-[0.2em] text-slate-500">Health Care</p><h3 class="mt-2 font-display text-lg font-semibold">1AD<span class="ml-2 text-sm text-slate-400">Adalta Limited</span></h3></div><div class="text-right"><p class="text-sm text-slate-300">A$<!-- -->0.01</p><p class="text-xs font-semibold text-red-400">-25.6<!-- -->% 1Y</p></div></div><p class="mt-4 text-sm text-slate-400">Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.</p><div class="mt-4 flex items-center justify-between text-xs text-slate-500"><span>Market cap <!-- -->A$11M</span><span class="text-blue-300">View analysis</span></div></a></div></div></div></section></div></main><footer class="border-t border-white/10 bg-ink-800/60"><div class="mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8"><div><h3 class="font-display text-lg font-semibold">ASX Desk</h3><p class="mt-3 text-sm text-slate-400">Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.</p><div class="mt-4 flex gap-3"><button class="rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white">Open an Account</button><button class="rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300">Download Media Kit</button></div></div><div class="grid grid-cols-2 gap-6 text-sm text-slate-400"><div><h4 class="mb-2 font-semibold text-slate-200">Platform</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/screener/">Screener</a></li><li><a class="hover:text-white" href="/news/">News &amp; Commentary</a></li><li><a class="hover:text-white" href="/about/">About</a></li></ul></div><div><h4 class="mb-2 font-semibold text-slate-200">Sectors</h4><ul class="space-y-2"><li><a class="hover:text-white" href="/sectors/materials/">Materials</a></li><li><a class="hover:text-white" href="/sectors/financials/">Financials</a></li><li><a class="hover:text-white" href="/sectors/health care/">Health Care</a></li><li><a class="hover:text-white" href="/sectors/information technology/">Information Tech</a></li><li><a class="hover:text-white" href="/sectors/energy/">Energy</a></li></ul></div></div><div class="glass-card rounded-2xl p-6"><h4 class="font-semibold">Weekly Alpha Briefing</h4><p class="mt-2 text-sm text-slate-400">Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.</p><div class="mt-4 flex flex-col gap-3 sm:flex-row"><input type="email" placeholder="you@example.com" class="w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"/><button class="rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white">Subscribe</button></div><p class="mt-3 text-xs text-slate-500">By subscribing you agree to receive marketing updates. Unsubscribe anytime.</p></div></div><div class="border-t border-white/10 py-6 text-center text-xs text-slate-500"><p>General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.</p></div></footer></div><script src="/_next/static/chunks/webpack-04cc3a393714a88b.js" async=""></script><script>(self.__next_f=self.__next_f||[]).push([0]);self.__next_f.push([2,null])</script><script>self.__next_f.push([1,"1:HL[\"/_next/static/media/26d4368bf94c0ec4-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n2:HL[\"/_next/static/media/36966cca54120369-s.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"type\":\"font/woff2\"}]\n3:HL[\"/_next/static/css/505959d5a855b2ce.css\",\"style\"]\n"])</script><script>self.__next_f.push([1,"4:I[5751,[],\"\"]\n7:I[2885,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js\"],\"default\"]\n8:I[231,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"669\",\"static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js\"],\"\"]\n9:I[9275,[],\"\"]\nb:I[1343,[],\"\"]\nc:I[8173,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"185\",\"static/chunks/app/layout-24f8abeacb8025a3.js\"],\"Image\"]\nd:I[5864,[\"231\",\"static/chunks/231-9e11bdfe3b664aec.js\",\"896\",\"static/chunks/896-78f6f35c40d7ae60.js\",\"185\",\"static/chunks/app/layout-24f8abeacb8025a3.js\"],\"default\"]\nf:I[6130,[],\"\"]\n6:T5fb,{\"@context\":\"https://schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does AVH do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Avita Medical develops and commercialises the RECELL System, an innovative regenerative medicine technology. This system uses a small sample of a patient's own skin to create a 'spray-on skin' solution, primarily for treating severe burns, and increasingly for vitiligo and other reconstructive skin procedures.\"}},{\"@type\":\"Question\",\"name\":\"Is AVH a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"AVH represents a speculative investment opportunity within the ASX biotech sector. It offers significant potential upside through the expanded adoption of its RECELL System and successful development of new indications. However, like many small-cap biotechs, it carries inherent risks, including dependence on clinical trial success, regulatory hurdles, market acceptance, and the ongoing need for capital raises to fund its growth ambitions.\"}},{\"@type\":\"Question\",\"name\":\"What drives AVH's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"AVH's share price is primarily driven by several factors specific to the biotech sector: growth in RECELL System sales, positive outcomes and progress from clinical trials for new indications, regulatory approvals (particularly from the FDA), news regarding reimbu"])</script><script>self.__next_f.push([1,"rsement pathways, and the company's ability to effectively manage its cash burn and secure funding for ongoing research and commercial expansion.\"}}]}a:[\"ticker\",\"AVH\",\"d\"]\n10:[]\n"])</script><script>self.__next_f.push([1,"0:[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/505959d5a855b2ce.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\"}]],[\"$\",\"$L4\",null,{\"buildId\":\"_aEgiWXeSCMrBLkgE2fk5\",\"assetPrefix\":\"\",\"initialCanonicalUrl\":\"/asx/AVH/\",\"initialTree\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"AVH\",\"d\"],{\"children\":[\"__PAGE__?{\\\"ticker\\\":\\\"AVH\\\"}\",{}]}]}]},\"$undefined\",\"$undefined\",true],\"initialSeedData\":[\"\",{\"children\":[\"asx\",{\"children\":[[\"ticker\",\"AVH\",\"d\"],{\"children\":[\"__PAGE__\",{},[[\"$L5\",[\"$\",\"div\",null,{\"className\":\"space-y-12\",\"children\":[[\"$\",\"script\",null,{\"type\":\"application/ld+json\",\"dangerouslySetInnerHTML\":{\"__html\":\"$6\"}}],[\"$\",\"section\",null,{\"className\":\"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]\",\"children\":[[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"Health Care\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":[\"Avita Medical Inc.\",\" (\",\"AVH\",\")\"]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-300\",\"children\":\"Avita Medical Inc. is a regenerative medicine company developing and commercialising the RECELL System, a medical device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of a patient’s own skin. This innovative technology is primarily used for the treatment of acute thermal burns, with expanding applications in vitiligo and reconstructive procedures, and its commercial operations are predominantly focused in the United States.\"}],[\"$\",\"div\",null,{\"className\":\"mt-6 grid gap-4 sm:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Market Cap\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"A$186M\"}]]}],[\"$\",\"div\",null,{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs text-slate-500\",\"children\":\"Shares on Issue\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-lg font-semibold\",\"children\":\"N/A\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"mt-6 flex flex-wrap gap-3 text-xs text-slate-400\",\"children\":[[\"$\",\"a\",null,{\"href\":\"\",\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Company Website\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"AI coverage updated hourly\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 px-3 py-1\",\"children\":\"Data from ASX filings\"}]]}]]}],[\"$\",\"$L7\",null,{\"ticker\":\"AVH\"}],[\"$\",\"section\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h2\",null,{\"className\":\"font-display text-xl font-semibold\",\"children\":\"AI Analysis\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm text-slate-300\",\"children\":[[\"$\",\"p\",\"Avita Medical is a revenue-generating small-cap biotech firm focused on expanding the adoption and indications for its proprietary RECELL System. Recent performance indicates growing revenue driven by increased product sales and market penetration, particularly within the burns treatment market in the US. The company is actively pursuing new regulatory approvals and indications, reflecting its transition from a pure R\u0026D play to a commercial-stage entity, though profitability may still be nascent as it reinvests heavily in growth and R\u0026D and requires ongoing capital management.\",{\"children\":\"Avita Medical is a revenue-generating small-cap biotech firm focused on expanding the adoption and indications for its proprietary RECELL System. Recent performance indicates growing revenue driven by increased product sales and market penetration, particularly within the burns treatment market in the US. The company is actively pursuing new regulatory approvals and indications, reflecting its transition from a pure R\u0026D play to a commercial-stage entity, though profitability may still be nascent as it reinvests heavily in growth and R\u0026D and requires ongoing capital management.\"}],[\"$\",\"p\",\"The growth outlook for Avita Medical is tied to broader adoption of the RECELL System across its approved indications (burns, vitiligo) and the successful expansion into new areas like soft tissue reconstruction. Upcoming catalysts include potential FDA approvals for new indications, publication of positive clinical trial data, and increased reimbursement coverage, which could significantly broaden market access. Strategically, the company is focused on scaling its commercial operations, deepening market penetration, and advancing its pipeline to leverage the RECELL technology platform for a wider range of dermatological and wound healing applications.\",{\"children\":\"The growth outlook for Avita Medical is tied to broader adoption of the RECELL System across its approved indications (burns, vitiligo) and the successful expansion into new areas like soft tissue reconstruction. Upcoming catalysts include potential FDA approvals for new indications, publication of positive clinical trial data, and increased reimbursement coverage, which could significantly broaden market access. Strategically, the company is focused on scaling its commercial operations, deepening market penetration, and advancing its pipeline to leverage the RECELL technology platform for a wider range of dermatological and wound healing applications.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid gap-6 lg:grid-cols-2\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-emerald-300\",\"children\":\"Bull Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Successful FDA approvals for new indications (e.g., soft tissue reconstruction, chronic wounds) and improved reimbursement pathways could significantly broaden market access and revenue potential for the RECELL System.\",{\"children\":[\"• \",\"Successful FDA approvals for new indications (e.g., soft tissue reconstruction, chronic wounds) and improved reimbursement pathways could significantly broaden market access and revenue potential for the RECELL System.\"]}],[\"$\",\"li\",\"Continued education and strong clinical data driving higher utilization rates of the RECELL System by plastic surgeons and burn specialists, leading to accelerated sales growth and deeper penetration in existing markets.\",{\"children\":[\"• \",\"Continued education and strong clinical data driving higher utilization rates of the RECELL System by plastic surgeons and burn specialists, leading to accelerated sales growth and deeper penetration in existing markets.\"]}],[\"$\",\"li\",\"Positive outcomes from ongoing or future clinical trials could de-risk the pipeline, attract further investment, and support broader commercialization efforts, potentially making AVH an acquisition target.\",{\"children\":[\"• \",\"Positive outcomes from ongoing or future clinical trials could de-risk the pipeline, attract further investment, and support broader commercialization efforts, potentially making AVH an acquisition target.\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"flex items-center gap-2 text-sm font-semibold text-red-300\",\"children\":\"Bear Case\"}],[\"$\",\"ul\",null,{\"className\":\"mt-4 space-y-2 text-sm text-slate-300\",\"children\":[[\"$\",\"li\",\"Unfavourable clinical trial results or significant delays in regulatory approval processes for new indications could hinder growth, increase cash burn, and impact investor confidence.\",{\"children\":[\"• \",\"Unfavourable clinical trial results or significant delays in regulatory approval processes for new indications could hinder growth, increase cash burn, and impact investor confidence.\"]}],[\"$\",\"li\",\"Slower-than-anticipated physician adoption due to factors like training requirements, cost-effectiveness concerns, or intense competition from alternative treatments could limit revenue growth and profitability.\",{\"children\":[\"• \",\"Slower-than-anticipated physician adoption due to factors like training requirements, cost-effectiveness concerns, or intense competition from alternative treatments could limit revenue growth and profitability.\"]}],[\"$\",\"li\",\"As a growth-stage biotech, Avita Medical may require further capital raises to fund ongoing R\u0026D and commercial expansion, potentially leading to significant shareholder dilution.\",{\"children\":[\"• \",\"As a growth-stage biotech, Avita Medical may require further capital raises to fund ongoing R\u0026D and commercial expansion, potentially leading to significant shareholder dilution.\"]}]]}]]}]]}]]}],null,[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Recent Announcements\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"0\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Statement of CDIs on issue - AVH\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"4 Feb 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Capital Structure\"}]]}],\"\"]}],[\"$\",\"div\",\"1\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Notification of cessation of securities - AVH\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"2 Feb 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Capital Structure\"}]]}],\"\"]}],[\"$\",\"div\",\"2\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Change of Director's Interest Notice\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"29 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Director Dealing\"}]]}],\"\"]}],[\"$\",\"div\",\"3\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Change of Director's Interest Notice\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"29 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Director Dealing\"}]]}],\"\"]}],[\"$\",\"div\",\"4\",{\"className\":\"rounded-xl border border-white/10 bg-ink-900/40 p-4\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex flex-wrap items-center gap-2\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Change of Director's Interest Notice\"}],false]}],[\"$\",\"div\",null,{\"className\":\"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":\"29 Jan 2026\"}],[\"$\",\"span\",null,{\"className\":\"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5\",\"children\":\"Director Dealing\"}]]}],\"\"]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"FAQs\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-3 text-sm text-slate-300\",\"children\":[[\"$\",\"div\",\"What does AVH do?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What does AVH do?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"Avita Medical develops and commercialises the RECELL System, an innovative regenerative medicine technology. This system uses a small sample of a patient's own skin to create a 'spray-on skin' solution, primarily for treating severe burns, and increasingly for vitiligo and other reconstructive skin procedures.\"}]]}],[\"$\",\"div\",\"Is AVH a good investment?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"Is AVH a good investment?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"AVH represents a speculative investment opportunity within the ASX biotech sector. It offers significant potential upside through the expanded adoption of its RECELL System and successful development of new indications. However, like many small-cap biotechs, it carries inherent risks, including dependence on clinical trial success, regulatory hurdles, market acceptance, and the ongoing need for capital raises to fund its growth ambitions.\"}]]}],[\"$\",\"div\",\"What drives AVH's share price?\",{\"className\":\"border-b border-white/5 pb-3\",\"children\":[[\"$\",\"p\",null,{\"className\":\"font-semibold text-white\",\"children\":\"What drives AVH's share price?\"}],[\"$\",\"p\",null,{\"className\":\"text-slate-400\",\"children\":\"AVH's share price is primarily driven by several factors specific to the biotech sector: growth in RECELL System sales, positive outcomes and progress from clinical trials for new indications, regulatory approvals (particularly from the FDA), news regarding reimbursement pathways, and the company's ability to effectively manage its cash burn and secure funding for ongoing research and commercial expansion.\"}]]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"space-y-6\",\"children\":[[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-semibold\",\"children\":\"Key Metrics\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4 text-sm\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Share Price\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":[\"A$\",\"1.14\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"1Y Performance\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold text-red-400\",\"children\":[\"-58.3\",\"%\"]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Market Cap\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"A$186M\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Shares on Issue\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"N/A\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"Sector\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"Health Care\"}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"span\",null,{\"className\":\"text-slate-400\",\"children\":\"IPO Date\"}],[\"$\",\"span\",null,{\"className\":\"font-semibold\",\"children\":\"24/06/2020\"}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"Related Stocks\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 space-y-4\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/asx/CSL\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"CSL\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"CSL Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"181.24\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-27.3\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$88.2B\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/PNV\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"PNV\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Polynovo Ltd\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.99\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-13.1\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$670M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}],[\"$\",\"$L8\",null,{\"href\":\"/asx/1AD\",\"className\":\"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.2em] text-slate-500\",\"children\":\"Health Care\"}],[\"$\",\"h3\",null,{\"className\":\"mt-2 font-display text-lg font-semibold\",\"children\":[\"1AD\",[\"$\",\"span\",null,{\"className\":\"ml-2 text-sm text-slate-400\",\"children\":\"Adalta Limited\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"text-right\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-sm text-slate-300\",\"children\":[\"A$\",\"0.01\"]}],[\"$\",\"p\",null,{\"className\":\"text-xs font-semibold text-red-400\",\"children\":[\"-25.6\",\"% 1Y\"]}]]}]]}],[\"$\",\"p\",null,{\"className\":\"mt-4 text-sm text-slate-400\",\"children\":\"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex items-center justify-between text-xs text-slate-500\",\"children\":[[\"$\",\"span\",null,{\"children\":[\"Market cap \",\"A$11M\"]}],[\"$\",\"span\",null,{\"className\":\"text-blue-300\",\"children\":\"View analysis\"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\",\"$a\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\",\"asx\",\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"notFoundStyles\":\"$undefined\",\"styles\":null}],null]},[[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"__variable_6d343d __variable_49a339\",\"children\":[[\"$\",\"head\",null,{\"children\":[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/logo.svg\",\"type\":\"image/svg+xml\"}]}],[\"$\",\"body\",null,{\"className\":\"min-h-screen bg-ink-900 text-slate-100\",\"children\":[\"$\",\"div\",null,{\"className\":\"min-h-screen\",\"children\":[[\"$\",\"header\",null,{\"className\":\"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8\",\"children\":[[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"flex items-center gap-3\",\"children\":[[\"$\",\"$Lc\",null,{\"src\":\"/logo.svg\",\"alt\":\"ASX Desk\",\"width\":140,\"height\":40,\"className\":\"h-10 w-auto\",\"priority\":true}],[\"$\",\"span\",null,{\"className\":\"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline\",\"children\":\"Research Terminal\"}]]}],[\"$\",\"nav\",null,{\"className\":\"hidden items-center gap-6 text-sm text-slate-300 md:flex\",\"children\":[[\"$\",\"$L8\",\"/\",{\"href\":\"/\",\"className\":\"transition hover:text-white\",\"children\":\"Home\"}],[\"$\",\"$L8\",\"/screener\",{\"href\":\"/screener\",\"className\":\"transition hover:text-white\",\"children\":\"Screener\"}],[\"$\",\"$L8\",\"/sectors\",{\"href\":\"/sectors\",\"className\":\"transition hover:text-white\",\"children\":\"Sectors\"}],[\"$\",\"$L8\",\"/news\",{\"href\":\"/news\",\"className\":\"transition hover:text-white\",\"children\":\"News\"}],[\"$\",\"$L8\",\"/compare/BHP-vs-RIO\",{\"href\":\"/compare/BHP-vs-RIO\",\"className\":\"transition hover:text-white\",\"children\":\"Compare\"}],[\"$\",\"$L8\",\"/about\",{\"href\":\"/about\",\"className\":\"transition hover:text-white\",\"children\":\"About\"}]]}],[\"$\",\"div\",null,{\"className\":\"hidden items-center gap-3 md:flex\",\"children\":[[\"$\",\"$Ld\",null,{}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20\",\"children\":\"Premium Research\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400\",\"children\":\"Open Account\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden\",\"children\":[[\"$\",\"div\",null,{\"className\":\"flex-1\",\"children\":[\"$\",\"$Ld\",null,{}]}],[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"shrink-0 text-xs text-blue-300\",\"children\":\"Screener\"}]]}]]}],[\"$\",\"main\",null,{\"className\":\"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8\",\"children\":[\"$\",\"$L9\",null,{\"parallelRouterKey\":\"children\",\"segmentPath\":[\"children\"],\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$Lb\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[\"$\",\"div\",null,{\"className\":\"flex min-h-[60vh] flex-col items-center justify-center text-center\",\"children\":[[\"$\",\"p\",null,{\"className\":\"text-xs uppercase tracking-[0.3em] text-blue-300\",\"children\":\"404\"}],[\"$\",\"h1\",null,{\"className\":\"mt-3 font-display text-3xl font-semibold\",\"children\":\"Page not found\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"We couldn't locate that ASX page. Try searching a ticker or visit the homepage.\"}],[\"$\",\"$L8\",null,{\"href\":\"/\",\"className\":\"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Back to Home\"}]]}],\"notFoundStyles\":[],\"styles\":null}]}],[\"$\",\"footer\",null,{\"className\":\"border-t border-white/10 bg-ink-800/60\",\"children\":[[\"$\",\"div\",null,{\"className\":\"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h3\",null,{\"className\":\"font-display text-lg font-semibold\",\"children\":\"ASX Desk\"}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-sm text-slate-400\",\"children\":\"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex gap-3\",\"children\":[[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Open an Account\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300\",\"children\":\"Download Media Kit\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"grid grid-cols-2 gap-6 text-sm text-slate-400\",\"children\":[[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Platform\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/screener\",\"className\":\"hover:text-white\",\"children\":\"Screener\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/news\",\"className\":\"hover:text-white\",\"children\":\"News \u0026 Commentary\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/about\",\"className\":\"hover:text-white\",\"children\":\"About\"}]}]]}]]}],[\"$\",\"div\",null,{\"children\":[[\"$\",\"h4\",null,{\"className\":\"mb-2 font-semibold text-slate-200\",\"children\":\"Sectors\"}],[\"$\",\"ul\",null,{\"className\":\"space-y-2\",\"children\":[[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/materials\",\"className\":\"hover:text-white\",\"children\":\"Materials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/financials\",\"className\":\"hover:text-white\",\"children\":\"Financials\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/health care\",\"className\":\"hover:text-white\",\"children\":\"Health Care\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/information technology\",\"className\":\"hover:text-white\",\"children\":\"Information Tech\"}]}],[\"$\",\"li\",null,{\"children\":[\"$\",\"$L8\",null,{\"href\":\"/sectors/energy\",\"className\":\"hover:text-white\",\"children\":\"Energy\"}]}]]}]]}]]}],[\"$\",\"div\",null,{\"className\":\"glass-card rounded-2xl p-6\",\"children\":[[\"$\",\"h4\",null,{\"className\":\"font-semibold\",\"children\":\"Weekly Alpha Briefing\"}],[\"$\",\"p\",null,{\"className\":\"mt-2 text-sm text-slate-400\",\"children\":\"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox.\"}],[\"$\",\"div\",null,{\"className\":\"mt-4 flex flex-col gap-3 sm:flex-row\",\"children\":[[\"$\",\"input\",null,{\"type\":\"email\",\"placeholder\":\"you@example.com\",\"className\":\"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500\"}],[\"$\",\"button\",null,{\"className\":\"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white\",\"children\":\"Subscribe\"}]]}],[\"$\",\"p\",null,{\"className\":\"mt-3 text-xs text-slate-500\",\"children\":\"By subscribing you agree to receive marketing updates. Unsubscribe anytime.\"}]]}]]}],[\"$\",\"div\",null,{\"className\":\"border-t border-white/10 py-6 text-center text-xs text-slate-500\",\"children\":[\"$\",\"p\",null,{\"children\":\"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results.\"}]}]]}]]}]}]]}],null],null],\"couldBeIntercepted\":false,\"initialHead\":[null,\"$Le\"],\"globalErrorComponent\":\"$f\",\"missingSlots\":\"$W10\"}]]\n"])</script><script>self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1\"}],[\"$\",\"meta\",\"1\",{\"charSet\":\"utf-8\"}],[\"$\",\"title\",\"2\",{\"children\":\"AVH share price, analysis \u0026 company profile - Avita Medical Inc. | ASX Desk\"}],[\"$\",\"meta\",\"3\",{\"name\":\"description\",\"content\":\"Latest AVH share price overview, what Avita Medical Inc. does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"link\",\"4\",{\"rel\":\"canonical\",\"href\":\"https://asxdesk.com/asx/AVH/\"}],[\"$\",\"meta\",\"5\",{\"property\":\"og:title\",\"content\":\"AVH share price, analysis \u0026 company profile - Avita Medical Inc.\"}],[\"$\",\"meta\",\"6\",{\"property\":\"og:description\",\"content\":\"Latest AVH share price overview, what Avita Medical Inc. does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"7\",{\"property\":\"og:url\",\"content\":\"https://asxdesk.com/asx/AVH/\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"9\",{\"name\":\"twitter:card\",\"content\":\"summary_large_image\"}],[\"$\",\"meta\",\"10\",{\"name\":\"twitter:title\",\"content\":\"AVH share price, analysis \u0026 company profile - Avita Medical Inc.\"}],[\"$\",\"meta\",\"11\",{\"name\":\"twitter:description\",\"content\":\"Latest AVH share price overview, what Avita Medical Inc. does, bull and bear cases, and AI-powered analysis for ASX investors.\"}],[\"$\",\"meta\",\"12\",{\"name\":\"next-size-adjust\"}]]\n5:null\n"])</script></body></html>